[18F]CSB-321 for Cancer

This trial explores a new imaging treatment, [18F]CSB-321 (a radiotracer), for individuals with advanced, inoperable cancer. Researchers will use PET scans to track how the treatment spreads through the body before and after starting specific cancer therapies, such as immunotherapy. The trial seeks participants diagnosed with metastatic cancer or uveal melanoma who plan to begin treatment with certain immune-related drugs. Participants should have tumors large enough for imaging and be willing to undergo study procedures. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot be on systemic steroids or immunosuppressive agents. If you are on corticosteroids, you may be allowed if the dose is less than 10 mg daily prednisone equivalent.

Research has shown that [18F]CSB-321 is being tested for safety in people with cancer. This study, currently in its early stages, primarily aims to assess the treatment's safety. Researchers closely monitor participants for any side effects after treatment, and so far, no serious issues have been reported. The study also examines how the treatment functions in the body and its potential effects on cancer. Although more information is needed, these early tests help confirm the treatment's general safety before progressing to larger studies.¹²³⁴⁵

Researchers are excited about [18F]CSB-321 because it offers a new approach to cancer imaging using PET scans. Unlike traditional imaging techniques, which may not always clearly distinguish cancerous tissues, [18F]CSB-321 utilizes a novel radiotracer that can potentially provide more precise and earlier detection of tumors. This enhanced imaging capability could lead to better treatment planning and monitoring, ultimately improving patient outcomes.

Research has shown that [18F]CSB-321 is under investigation in this trial to determine its potential to enhance cancer treatment. This involves PET imaging, a scan that helps doctors assess how cancer responds to treatment. All participants in this trial will receive up to three doses of [18F]CSB-321 along with the corresponding PET imaging. This imaging allows scientists to evaluate the effectiveness of immunotherapy in patients with advanced cancers. Early results suggest that PET imaging with [18F]CSB-321 might help predict the effectiveness of cancer treatments. Although data remains limited, the aim is that improved imaging will lead to better treatment choices and outcomes.¹³⁵⁶⁷